Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI258 plus fulvestrant versus placebo plus fulvestrant in hormone receptor-positive HER2-negative advanced breast cancer
NL-OMON39886Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dovitinib and fulvestrant in breast cancer, sponsored by Novartis. Started Oct 2012; status: active, not recruiting.
02
Drugs
dovitinibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON39886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39886.